PCS
ADAP

Personal CFO Solutions’s Adaptimmune Therapeutics ADAP Stock Holding History

Personal CFO Solutions’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-19,388
Closed -$17.9K – 456
2023
Q2 		$17.9K Hold
19,388
– – ﹤0.01% 466
2023
Q1 		$21.1K Hold
19,388
– – ﹤0.01% 467
2022
Q4 		$28.3K Hold
19,388
– – 0.01% 451
2022
Q3 		$21K Sell
19,388
-3,000
-13% -$5.51K 0.01% 409
2022
Q2 		$38K Sell
22,388
-4,000
-15% -$6.87K 0.01% 423
2022
Q1 		$54K Hold
26,388
– – 0.01% 458
2021
Q4 		$99K Sell
26,388
-10,000
-27% -$45.5K 0.02% 461
2021
Q3 		$188K Buy
36,388
+6,000
+20% +$26.9K 0.04% 423
2021
Q2 		$129K Buy
30,388
+16,500
+119% +$80.1K 0.03% 417
2021
Q1 		$74K Buy
13,888
+2,000
+17% +$11.4K 0.02% 397
2020
Q4 		$64K Sell
11,888
-13,909
-54% -$75.6K 0.02% 366
2020
Q3 		$0 Buy
+25,797
New +$226K ﹤0.01% 137

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Personal CFO Solutions's ADAP Position: Q3 2023 in Review

Personal CFO Solutions sold out of Adaptimmune Therapeutics (ADAP) in Q3 2023, closing a stake of 19,388 shares — an estimated $17.9K sold.

Personal CFO Solutions first reported a position in ADAP in Q3 2020 and held it in 12 quarters. The position peaked at $188K in Q3 2021. 79 funds tracked by Wall St. Rank hold ADAP as of Q3 2023.

  • Personal CFO Solutions reported no remaining Adaptimmune Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Personal CFO Solutions sold 19,388 Adaptimmune Therapeutics shares in Q3 2023, an estimated $17.9K.
  • Personal CFO Solutions first reported a position in Adaptimmune Therapeutics in Q3 2020 and held it in 12 quarters.
  • Personal CFO Solutions's Adaptimmune Therapeutics position peaked at $188K in Q3 2021.
  • 79 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2023.

Based on Personal CFO Solutions's 13F filing for Q3 2023, filed 13 Nov 2023.